Donepezil for severe Alzheimers disease

被引：18

作者：

Hogan, DB ^{[1
]}

机构：

[1] Univ Calgary, Hlth Sci Ctr, Div Geriatr Med, Calgary, AB T2N 4N1, Canada

来源：

LANCET | 2006年 / 367卷 / 9516期

关键词：

D O I：

10.1016/S0140-6736(06)68395-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1031 / 1032

页数：2

共 10 条

[1]

Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33

[2]

Gasper Mason C, 2005, Am J Geriatr Pharmacother, V3, P1, DOI 10.1016/j.amjopharm.2005.02.001

[3]

Last JM, 2001, DICT EPIDEMIOLOGY, P129

[4] Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease [J].

Lopez, OL ;

Becker, JT ;

Wisniewski, S ;

Saxton, J ;

Kaufer, DI ;

Dekosky, ST .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (03) :310-314

[5] SEVERE IMPAIRMENT BATTERY - A NEUROPSYCHOLOGICAL TEST FOR SEVERELY DEMENTED PATIENTS [J].

PANISSET, M ;

ROUDIER, M ;

SAXTON, J ;

BOLLER, F .

ARCHIVES OF NEUROLOGY, 1994, 51 (01) :41-45

[6] Goal setting and attainment in Alzheimer's disease patients treated with donepezil [J].

Rockwood, K ;

Graham, JE ;

Fay, S .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (05) :500-507

[7]

Streiner DL, 2002, CAN J PSYCHIAT, V47, P68

[8] Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases [J].

Unnebrink, K ;

Windeler, J .

STATISTICS IN MEDICINE, 2001, 20 (24) :3931-3946

[9] Surveying physicians to determine the minimal important difference: Implications for sample-size calculation [J].

van Walraven, C ;

Mahon, JL ;

Moher, D ;

Bohm, C ;

Laupacis, A .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (08) :717-723

[10] Donepezil in patients with severe Alzheimer's disease:: double-blind, parallel-group, placebo-controlled study [J].

Winblad, B ;

Kilander, L ;

Eriksson, S ;

Minthon, L ;

Båtsman, S ;

Wetterholm, AL ;

Jarisson-Blixt, C ;

Hoglund, A .

LANCET, 2006, 367 (9516) :1057-1065

← 1 →